US 12,419,931 B2
Anti-cancer composition
Johannes Francois Marais, Potchefstroom (ZA); Jacobus Johannes Van Jaarsveld, Potchefstroom (ZA); and James Clive Hurwitz Laporta, Cape Town (ZA)
Assigned to ACUPHARM INTERNATIONAL PROPRIETARY LIMITED, Gaborone (BW)
Appl. No. 18/268,233
Filed by ACUPHARM INTERNATIONAL PROPRIETARY LIMITED, Gaborone (BW)
PCT Filed Dec. 15, 2021, PCT No. PCT/IB2021/061744
§ 371(c)(1), (2) Date Jun. 18, 2023,
PCT Pub. No. WO2022/130225, PCT Pub. Date Jun. 23, 2022.
Claims priority of application No. 2027153 (NL), filed on Dec. 18, 2020.
Prior Publication US 2024/0293498 A1, Sep. 5, 2024
Int. Cl. A61K 36/9066 (2006.01); A61K 36/48 (2006.01); A61P 35/00 (2006.01)
CPC A61K 36/9066 (2013.01) [A61K 36/48 (2013.01); A61P 35/00 (2018.01); A61K 2236/333 (2013.01); A61K 2236/53 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A composition for use in the treatment of cancer, the composition including:
an aqueously-soluble extract of curcumin;
an aqueously-soluble extract of Sutherlandia frutescens (“Sutherlandia”); and
an aqueous carrier solution.